Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunity

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Phua, Kyle K L ^a,b   Staats, Herman F ^c   Leong, Kam W ^a,c   Nair, Smita K ^c  

^a Duke University   (United States)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; MESSENGER RNA; NANOPARTICLE;

ANIMAL; C57BL MOUSE; CELL SURVIVAL; CHEMISTRY; DRUG FORMULATION; FEMALE; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; MOUSE; NEOPLASMS, EXPERIMENTAL; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME; TUMOR CELL LINE; ULTRASTRUCTURE;

ADMINISTRATION, INTRANASAL; ANIMALS; CANCER VACCINES; CELL LINE, TUMOR; CELL SURVIVAL; DRUG COMPOUNDING; FEMALE; MICE; MICE, INBRED C57BL; NANOPARTICLES; NEOPLASMS, EXPERIMENTAL; RNA, MESSENGER; TREATMENT OUTCOME;

EID: 84902097227     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep05128     Document Type: Article

References (51)

1. Caruso, D. A. et al. Results of a phase 1 study utilizingmonocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer. Neuro Oncol 6, 236-246 (2004).
2. Coosemans, A. et al. Immunological response after therapeutic vaccination with WT1 mRNA-loaded dendritic cells in end-stage endometrial carcinoma. Anticancer Res 30, 3709-3714 (2010).
3. Morse, M. A. et al. Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA. Cancer Invest 21, 341-349 (2003).
4. Rains, N., Cannan, R. J., Chen,W. & Stubbs, R. S. Development of a dendritic cell (DC)-based vaccine for patients with advanced colorectal cancer. Hepatogastroenterology 48, 347-351 (2001).
5. Steitz, J., Britten, C. M., Wolfel, T. & Tuting, T. Effective induction of antimelanoma immunity following genetic vaccination with synthetic mRNA coding for the fusion protein EGFP.TRP2. Cancer Immunol Immunother 55, 246-253 (2006).
6. Su, Z. et al. Telomerase mRNA-transfected dendritic cells stimulate antigenspecific CD81 and CD41 T cell responses in patients with metastatic prostate cancer. J Immunol 174, 3798-3807 (2005).
7. Van Lint, S., Heirman, C., Thielemans, K.&Breckpot, K. mRNA: From a chemical blueprint for protein production to an off-the-shelf therapeutic. Hum Vaccin Immunother 9 (2013).
8. Nair, S., Boczkowski, D., Pruitt, S. & Urban, J. RNA in cancer vaccine therapy in Cancer Vaccines: From Research To Clinical Practice (ed Bot, A., Obrocea, M. & Marincola, F.) Ch. 16, 217-231 (Informa Healthcare, 2011).
9. Dannull, J. et al. Melanoma immunotherapy using mature DCs expressing the constitutive proteasome. J Clin Invest 123, 3135-3145, doi:10.1172/JCI67544 (2013).
10. Phua, K. K. et al. Whole Blood Cells Loaded with Messenger RNA as an Anti-Tumor Vaccine. Adv Healthc Mater, doi:10.1002/adhm.201300512 (2013).
11. Walch, B., Breinig, T., Schmitt, M. J. & Breinig, F. Delivery of functional DNA and messenger RNA to mammalian phagocytic cells by recombinant yeast. Gene Ther 19, 237-245, doi:10.1038/gt.2011.121 (2012).
12. Kreiter, S. et al. Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res 70, 9031-9040, doi:10.1158/0008-5472.CAN-10-0699 (2010).
13. Van Lint, S. et al. Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy. Cancer Res 72, 1661-1671, doi:10.1158/0008-5472. CAN-11-2957 (2012).
14. Hess, P. R., Boczkowski, D., Nair, S. K., Snyder, D. & Gilboa, E. Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor/self antigen. Cancer Immunol Immunother 55, 672-683, doi:10.1007/s00262-005-0064-z (2006).
15. Hoerr, I., Obst, R., Rammensee, H. G. & Jung, G. In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur J Immunol 30, 1-7 (2000).
16. Mockey, M. et al. mRNA-based cancer vaccine: prevention of B16 melanoma progression and metastasis by systemic injection of MART1 mRNA histidylated lipopolyplexes. Cancer Gene Ther 14, 802-814, doi:10.1038/sj.cgt.7701072 (2007).
17. Perche, F. et al. Enhancement of dendritic cells transfection in vivo and of vaccination against B16F10 melanoma with mannosylated histidylated lipopolyplexes loaded with tumor antigen messenger RNA. Nanomedicine 7, 445-453, doi:10.1016/j.nano.2010.12.010 (2011).
18. Pollard, C. et al. Type I IFN Counteracts the Induction of Antigen-Specific Immune Responses by Lipid-Based Delivery of mRNA Vaccines. Mol Ther 21, 251-259, doi:Doi 10.1038/Mt.2012.202 (2013).
19. Zhou, W. Z. et al. RNA melanoma vaccine: induction of antitumor immunity by human glycoprotein 100 mRNA immunization. Hum Gene Ther 10, 2719-2724, doi:10.1089/10430349950016762 (1999).
20. Kariko, K.,Muramatsu, H., Keller, J. M. &Weissman, D. Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin. Mol Ther 20, 948-953, doi:10.1038/mt.2012.7 (2012).
21. Su, X. F., Fricke, J., Kavanagh, D. G. & Irvine, D. J. In Vitro and in Vivo mRNA Delivery Using Lipid-Enveloped pH-Responsive Polymer Nanoparticles. Molecular Pharmaceutics 8, 774-787, doi:Doi 10.1021/Mp100390w (2011).
22. Zohra, F. T., Chowdhury, E. H., Nagaoka, M. & Akaike, T. Drastic effect of nanoapatite particles on liposome-mediated mRNA delivery to mammalian cells. Analytical Biochemistry 345, 164-166, doi:Doi 10.1016/J.Ab.2005.06.031 (2005).
23. Zou, S., Scarfo, K.,Nantz, M. H. &Hecker, J. G. Lipid-mediated delivery of RNA is more efficient than delivery of DNA in non-dividing cells. Int J Pharmaceut 389, 232-243, doi:DOI 10.1016/j.ijpharm.2010.01.019 (2010).
24. Phua, K. K., Leong, K. W. & Nair, S. K. Transfection efficiency and transgene expression kinetics of mRNA delivered in naked and nanoparticle format. J Control Release 166, 227-233, doi:10.1016/j.jconrel.2012.12.029 (2013).
25. Nochi, T. et al. Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines. Nat Mater 9, 572-578, doi:10.1038/nmat2784 (2010).
26. Lorenzi, J. C. et al. Intranasal vaccination with messenger RNA as a new approach in gene therapy: use against tuberculosis. BMC Biotechnol 10, 77, doi:10.1186/1472-6750-10-77 (2010).
27. Porgador, A., Staats, H. F., Faiola, B., Gilboa, E. & Palker, T. J. Intranasal immunization with CTL epitope peptides from HIV-1 or ovalbumin and the mucosal adjuvant cholera toxin induces peptide-specific CTLs and protection against tumor development in vivo. J Immunol 158, 834-841 (1997).
28. Cesta, M. F. Normal structure, function, and histology of mucosa-associated lymphoid tissue. Toxicol Pathol 34, 599-608, doi:10.1080/01926230600865531 (2006).
29. Gwinn, W. M. et al. Effective induction of protective systemic immunity with nasally administered vaccines adjuvanted with IL-1. Vaccine 28, 6901-6914, doi:10.1016/j.vaccine.2010.08.006 (2010).
30. Mehrara, E., Forssell-Aronsson, E., Ahlman, H. & Bernhardt, P. Specific growth rate versus doubling time for quantitative characterization of tumor growth rate. Cancer Res 67, 3970-3975, doi:Doi 10.1158/0008-5472.Can-06- 3822 (2007).
31. Antonia, S. J., Extermann,M. & Flavell, R. A. Immunologic nonresponsiveness to tumors. Crit Rev Oncog 9, 35-41 (1998).
32. Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J. & Schreiber, R. D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3, 991-998, doi:10.1038/ni1102-991 (2002).
33. Marincola, F. M., Jaffee, E. M., Hicklin, D. J. & Ferrone, S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 74, 181-273 (2000).
34. Bodmer, W. F. et al. Tumor escape from immune response by variation in HLA expression and other mechanisms. Ann N Y Acad Sci 690, 42-49 (1993).
35. Baumgartner, J. et al. Melanoma induces immunosuppression by up-regulating FOXP3(1) regulatory T cells. J Surg Res 141, 72-77, doi:10.1016/j.jss.2007.03.053 (2007).
36. Rabinovich, G. A., Gabrilovich, D. & Sotomayor, E. M. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 25, 267-296, doi:10.1146/annurev.immunol.25.022106.141609 (2007).
37. Aptsiauri, N. et al. Role of altered expression of HLA class I molecules in cancer progression. Adv Exp Med Biol 601, 123-131 (2007).
38. Restifo, N. P. et al. Molecular mechanisms used by tumors to escape immune recognition: immunogenetherapy and the cell biology of major histocompatibility complex class I. J Immunother Emphasis Tumor Immunol 14, 182-190 (1993).
39. Paschen, A. et al. Complete loss of HLA class I antigen expression on melanoma cells: a result of successive mutational events. Int J Cancer 103, 759-767, doi:10.1002/ijc.10906 (2003).
40. Sampson, J. H. et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 28, 4722-4729, doi:10.1200/JCO.2010.28.6963 (2010).
41. Fernandez, S., Cisney, E. D. & Ulrich, R. G. Enhancement of Serum and Mucosal Immune Responses to a Haemophilus influenzae Type B Vaccine by Intranasal Delivery. Clin Vaccine Immunol 20, 1690-1696, doi:10.1128/Cvi.00215- 13 (2013).
42. Li, Y. H. et al. Enhanced immunogenicity of an anti-caries vaccine encoding a cellsurface protein antigen of Streptococcus mutans by intranasal DNA primeprotein boost immunization. J Gene Med 11, 1039-1047, doi:Doi 10.1002/Jgm.1386 (2009).
43. Mohan, T., Mitra, D. & Rao, D. N. Nasal delivery of PLG microparticle encapsulated defensin peptides adjuvanted gp41 antigen confers strong and longlasting immunoprotective response against HIV-1. Immunol Res 58, 139-153, doi:DOI 10.1007/s12026-013-8428-5 (2014).
44. Nguyen, C. T., Kim, S. Y., Kim, M. S., Lee, S. E. & Rhee, J. H. Intranasal immunization with recombinant PspA fused with a flagellin enhances crossprotective immunity against Streptococcus pneumoniae infection in mice. Vaccine 29, 5731-5739, doi:10.1016/j.vaccine.2011.05.095 (2011).
45. Pontes, D. et al. Immune Response Elicited by DNA Vaccination Using Lactococcus lactis Is Modified by the Production of Surface Exposed Pathogenic Protein. Plos One 9, doi:10.1371/journal.pone.0084509 (2014).
46. Torrieri-Dramard, L. et al. Intranasal DNA vaccination induces potent mucosal and systemic immune responses and cross-protective immunity against influenza viruses. Mol Ther 19, 602-611, doi:10.1038/mt.2010.222 (2011).
47. Wu, Y. B. et al. Thermal-sensitive hydrogel as adjuvant-free vaccine delivery system for H5N1 intranasal immunization. Biomaterials 33, 2351-2360, doi:10.1016/j.biomaterials.2011.11.068 (2012).
48. Matsuo, K. et al. Intranasal immunization with poly(gamma-glutamic acid) nanoparticles entrapping antigenic proteins can induce potent tumor immunity. J Control Release 152, 310-316, doi:10.1016/j.jconrel.2011.03.009 (2011).
49. Yao, W., Peng, Y., Du, M., Luo, J. & Zong, L. Preventative vaccine-loaded mannosylated chitosan nanoparticles intended for nasal mucosal delivery enhance immune responses and potent tumor immunity. Mol Pharm 10, 2904-2914, doi:10.1021/mp4000053 (2013).
50. Nair, S. K. et al. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat Med 6, 1011-1017, doi:10.1038/79519 (2000).
51. Nair, S. et al. Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation. J Immunol 171, 6275-6282 (2003).